Interim analysis of an open-label randomized controlled trial evaluating nasal irrigations in non-hospitalized patients with coronavirus disease 2019

被引：30

作者：

Kimura, Kyle S. ^{[1
]}

Freeman, Michael H. ^{[1
]}

Wessinger, Bronson C. ^{[2
]}

Gupta, Veerain ^{[2
]}

Sheng, Quanhu ^{[3
]}

Huang, Li Ching ^{[3
]}

Von Wahlde, Kate ^{[1
]}

Das, Suman R. ^{[1
,4
]}

Chowdhury, Naweed I. ^{[1
]}

Turner, Justin H. ^{[1
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 1215 21st Ave South,Suite 7209, Nashville, TN 37232 USA

[2] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[3] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN USA

[4] Vanderbilt Univ, Sch Med, Dept Med, Div Microbiol & Infect Dis, Nashville, TN 37212 USA

来源：

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY | 2020年 / 10卷 / 12期

关键词：

saline; coronavirus; COVID-19; irrigation; nasal;

D O I：

10.1002/alr.22703

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

引用

页码：1325 / 1328

页数：4

共 50 条

[41] Oseltamivir for coronavirus illness: post-hoc exploratory analysis of an open-label, pragmatic, randomised controlled trial in European primary care from 2016 to 2018
Coenen, Samuel
van Der Velden, Alike W.
Cianci, Daniela
Goossens, Herman
Bongard, Emily
Saville, Benjamin R.
Gobat, Nina
de Paor, Muireann
Leven, Margareta
Verheij, Theo J.
Butler, Christopher C.
BRITISH JOURNAL OF GENERAL PRACTICE, 2020, 70 (696) : E444 - E449
[42] Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
Amirreza Roostaei Firozabad
Zohreh Akhoundi Meybodi
Seyed Ruhollah Mousavinasab
Adeleh Sahebnasagh
Mohsen Gholinataj Jelodar
Iman Karimzadeh
Solomon Habtemariam
Fatemeh Saghafi
BMC Infectious Diseases, 21
[43] Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial
Firozabad, Amirreza Roostaei
Meybodi, Zohreh Akhoundi
Mousavinasab, Seyed Ruhollah
Sahebnasagh, Adeleh
Jelodar, Mohsen Gholinataj
Karimzadeh, Iman
Habtemariam, Solomon
Saghafi, Fatemeh
BMC INFECTIOUS DISEASES, 2021, 21 (01)
[44] Cardiac Adverse Events and Remdesivir in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
Terzic, Vida
Basilua, Joe Miantezila
Billard, Nicolas
de Gastines, Lucie
Belhadi, Drifa
Fougerou-Leurent, Claire
Peiffer-Smadja, Nathan
Mercier, Noemie
Delmas, Christelle
Ferrane, Assia
Dechanet, Aline
Poissy, Julien
Esperou, Helene
Ader, Florence
Hites, Maya
Andrejak, Claire
Greil, Richard
Paiva, Jose-Artur
Staub, Therese
Tacconelli, Evelina
Burdet, Charles
Costagliola, Dominique
Mentre, France
Yazdanpanah, Yazdan
Diallo, Alpha
CLINICAL INFECTIOUS DISEASES, 2024, 79 (02) : 382 - 391
[45] Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
Mohammad Bosaeed
Ebrahim Mahmoud
Ahmad Alharbi
Hadeel Altayib
Hawra Albayat
Faisal Alharbi
Khalid Ghalilah
Abdulmajid Al Arfaj
Jumana AlJishi
Abdullatif Alarfaj
Hajar Alqahtani
Badriah M. Almutairi
Manar Almaghaslah
Nawaf M. Alyahya
Abdullah Bawazir
Saud AlEisa
Abdulrahman Alsaedy
Abderrezak Bouchama
Malak Alharbi
Majid AlShamrani
Sameera Al Johani
Majed Aljeraisy
Mohammed Alzahrani
Abdulhakeem O. Althaqafi
Hassan Almarhabi
Athari Alotaibi
Nasser Alqahtani
Yaseen M. Arabi
Omar S. Aldibasi
Ahmad Alaskar
Infectious Diseases and Therapy, 2021, 10 : 2291 - 2307
[46] Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
Diago-Sempere, Elena
Bueno, Jose Luis
Sancho-Lopez, Aranzazu
Rubio, Elena Munez
Torres, Ferran
de Molina, Rosa Malo
Fernandez-Cruz, Ana
de Diego, Isabel Salcedo
Velasco-Iglesias, Ana
Payares-Herrera, Concepcion
Flecha, Inmaculada Casas
Avendano-Sola, Cristina
Palomino, Rafael Duarte
Ramos-Martinez, Antonio
Ruiz-Antoran, Belen
TRIALS, 2021, 22 (01)
[47] Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
Bosaeed, Mohammad
Mahmoud, Ebrahim
Alharbi, Ahmad
Altayib, Hadeel
Albayat, Hawra
Alharbi, Faisal
Ghalilah, Khalid
Al Arfaj, Abdulmajid
AlJishi, Jumana
Alarfaj, Abdullatif
Alqahtani, Hajar
Almutairi, Badriah M.
Almaghaslah, Manar
Alyahya, Nawaf M.
Bawazir, Abdullah
AlEisa, Saud
Alsaedy, Abdulrahman
Bouchama, Abderrezak
Alharbi, Malak
AlShamrani, Majid
Al Johani, Sameera
Aljeraisy, Majed
Alzahrani, Mohammed
Althaqafi, Abdulhakeem O.
Almarhabi, Hassan
Alotaibi, Athari
Alqahtani, Nasser
Arabi, Yaseen M.
Aldibasi, Omar S.
Alaskar, Ahmad
INFECTIOUS DISEASES AND THERAPY, 2021, 10 (04) : 2291 - 2307
[48] Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial
Golan, Yoav
Campos, Jesus Abraham Simon
Woolson, Rob
Cilla, Donald
Hanabergh, Rodolfo
Gonzales-Rojas, Yaneicy
Lopez, Reynaldo
Finberg, Robert
Balboni, Armand
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E10 - E17
[49] OR32. Efficacy and Safety of Therapeutic Versus Prophylactic Dose of Anticoagulation in Hospitalized Patients with Severe COVID-19 Pneumonia and Coagulopathy: An Open-Label, Randomized Controlled Trial
Adrian, L. H.
Hutomo, S. A.
Negari, A. D. S.
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (SUPPL F)
[50] Colchicine and/or Naltrexone for Hospitalized COVID-19 Patients Not Requiring High Levels of Ventilatory Support (COLTREXONE): A Prospective, Randomized, Open-Label Trial
Gertner, Elie
Schullo-Feulner, Anne
Knutson, Alison
Chrenka, Ella
O'Brien, Meghan
Behrendt, Christine
Johnson, Joseph
Delaney, Daniel
CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)

← 1 2 3 4 5 →